]>
IRCT20150725023332N5 IRCT 2021-04-06 Shahid Beheshti University of Medical Sciences The effect of hesperidin use on the clinical condition of patients with the new coronavirus Investigating the effectiveness of the use of hesperidin on the clinical conditions of patients with the new coronavirus (SARS-COV-2) 2020-06-21 anticipated 60 Complete https://irct.ir/trial/49150 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: With simple randomization and using a random number table and individual randomization unit. To randomize, we use a table consisting of random digits 0 to 9. Each digit of this table is repeated the same on average. There is no pattern of recognizable numbers. In this method, each number is assigned to a treatment group. We start from the first line of the table and move down line by line. For the two treatments, we put the numbers 0 to 4 for treatment A and the numbers 5 to 9 for treatment B. The numbers in the first line of the table are as follows: 0,5,2,7,8,4,3,7,4,1,6,8,3,8,5,1,5,6,9,6, ... Now for people based on the above numbers, we have the following allocation: A, B, A, B, B,... We will continue the above process until the two groups are completed, Blinding description: To prevent any possible complications, the primary caregiver is aware of the allocation of treatment groups. Patients in the study were also not blinded to the treatment they were receiving. Researchers responsible for data collection and analysis are not aware of the allocation of different study groups. 3 Covid-19. Intervention 1: Intervention group: Patients in this group, in addition to conventional treatment, receive 1 mg of hesperidin orally every 6 hours for 5 days. Intervention 2: control group: Patients in this group receive only conventional therapies, and hesperidin will not be prescribed. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Uncertainty in the timing of completion of the project.
public Alireza jahangirifard
The Hospital of Messiah Daneshvari, Darabad
Tehran Iran (Islamic Republic of) 1956944413 +98 21 2712 2537 Alirezajahangiri@sbmu.ac.ir Shahid Beheshti University of Medical Sciences scientific Behrooz Farzanegan
The Hospital of Messiah Daneshvari, Darabad
Tehran Iran (Islamic Republic of) 1956944413 +98 21 2712 2537 Farzaneganbehrooz@gmail.com Shahid Beheshti University of Medical Sciences Iran (Islamic Republic of) Patients with new coronavirus who hospitalized in the intensive care unit 18 years 65 years Both Patients with intubation conditions History of severe liver disease History of severe renal disease Patient dissatisfaction to participate in the project Age over 65 and under 18 years U07.02 COVID-19, virus not identified Treatment - Drugs Treatment - Drugs Intervention group: Patients in this group, in addition to conventional treatment, receive 1 mg of hesperidin orally every 6 hours for 5 days. control group: Patients in this group receive only conventional therapies, and hesperidin will not be prescribed. Lactate dehydrogenase. Timepoint: Before prescribing of Hesperidin and 5 days after taking it. Method of measurement: Lactate dehydrogenase testing by blood sampling. Cratinin. Timepoint: Before prescribing of Hesperidin and 5 days after taking it. Method of measurement: Testing for creatinine in the serum. BUN. Timepoint: Before prescribing of Hesperidin and 5 days after taking it. Method of measurement: Blood urea test. Shahid Beheshti University of Medical Sciences Approved 2020-05-26 Ethics Committee in Biomedical Research, Shahid Beheshti University Next to Ayatollah Taleghani Hospital ,Evin , Tehran, Iran Tehran Tehran Iran (Islamic Republic of)